Cannpal Animal Therapeutics

What Cannpal Animal Therapeutics does

Cannpal Animal Therapeutics is an Australia-based pharmaceutical-focused animal health company developing cannabinoid-derived therapeutic products for companion animals. Founded in 2016 and listed on the Australian Stock Exchange (ASX:CP1) in 2017, the company is now a wholly-owned subsidiary of AusCann Group Holdings (ASX:AC8). Cannpal's product portfolio targets the endocannabinoid system with both prescription pharmaceutical candidates (CPAT-01/CPAT-01D for pain and inflammation in dogs; CPAT-01C for cats) and a non-prescription nutraceutical (DermaCann for canine skin health). The lead asset CPAT-01D is a proprietary oral liquid combining CBD and THC and had completed Phase 1A pharmacokinetic and safety studies (11 dogs, no adverse events) with Phase 1B (48 dogs) underway as of late 2018; a provisional patent application has been filed in Australia covering safe cannabinoid dosages and ratios for dogs.

The underlying technology is a cannabinoid-derived therapeutic platform using proprietary CBD/THC combinations, with enhanced drug delivery systems developed under a CSIRO research collaboration to improve bioavailability. Cannpal differentiates through standardized, clinically validated formulations and mechanistic research using customized RT-PCR arrays covering 350+ genetic markers to characterize cannabinoid effects on pain and inflammation pathways. The business model is enterprise GTM via prescription: products are designed to be sold through licensed veterinarians upon regulatory approval, with parallel filings across Australia's APVMA, the US FDA/CVM (INAD filed), and the EMA in Europe (SME status granted). Revenue streams will eventually include prescription pharmaceutical sales and over-the-counter nutraceutical sales, both routed through the veterinary channel. The company is currently pre-commercial, with no disclosed revenue, and is funded primarily through its parent AusCann and a modest CSIRO Kick-Start grant (AUD $50K).

Name

Cannpal Animal Therapeutics

Legal name

CannPal Animal Therapeutics Limited

Website

https://cannpal.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Cannpal Animal Therapeutics is an Australian pre-clinical animal health company developing cannabinoid-derived prescription pharmaceuticals and nutraceuticals for companion animals, with lead asset CPAT-01D (canine pain) in Phase 1B trials and DermaCann (canine skin health) in development, distributed via veterinarians upon regulatory approval in Australia, US, and Europe.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Animal Food Manufacturing (3111)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Specialty Therapeutics (HLAMAEAJ)

akta.pro secondary industries

Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF), Dermatology & Allergy Drugs (HLAMAEAH), Species-Specific Supplements (Dog/Cat/Other Companion Species) (HLAMALAN)

Keywords

• Veterinary pharmaceuticals
• Cannabinoid therapeutics
• Companion animal health
• Pet nutraceuticals
• Animal drug development

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Prescriptions (CPAT-01): Revenue from regulatory-approved prescription veterinary medicines containing CBD and THC for pain and inflammation in companion animals, sold through veterinarians upon regulatory approval in target markets (Australia, US, Europe).
2. Nutraceuticals and Dietary Supplements (DermaCann): Revenue from non-prescription therapeutic products using hemp-derived compounds for canine skin health, sold through alternative regulatory pathways with potentially earlier market access than pharmaceutical products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Cannpal Animal Therapeutics is a pharmaceutical-focused animal health company developing regulatory-approved cannabinoid-derived therapeutic products for companion animals (dogs and cats). Its pipeline includes CPAT-01/CPAT-01D, an oral CBD/THC pharmaceutical for pain and inflammation in dogs, CPAT-01C for cats, and DermaCann, a hemp-derived nutraceutical for canine skin health. The company is pursuing veterinary medicinal product approvals in Australia (APVMA), the United States (FDA/CVM INAD), and Europe (EMA VMP).

Product overview

CannPal Animal Therapeutics is a pharmaceutical-focused animal health company developing both prescription (pharmaceuticals) and non-prescription (nutraceuticals) products derived from cannabis and hemp plants for companion animals. The company's product portfolio centers on CPAT-01/CPAT-01D, a lead pharmaceutical drug candidate containing CBD and THC for pain and inflammation in dogs, currently in Phase 1B clinical trials with a cat extension (CPAT-01C) in development. The nutraceutical pipeline includes DermaCann, a hemp-derived oral formulation targeting canine skin health. Educational resources are provided through the Resource Centre platform. All products target the endocannabinoid system in animals and aim for regulatory approval as veterinary medicines.

Differentiator

Problem solved

Functional benefit

Brands

• CPAT-01: Lead drug candidate - cannabis-derived therapeutic product being developed to target pain and inflammation in companion animals, with focus on dogs. Contains proprietary combination of CBD and THC in standardized oral liquid formulation.
• DermaCann
• CPAT-01C

Products and services

• CPAT-01 / CPAT-01D Lead pharmaceutical drug candidate: an oral liquid formulation containing proprietary combination of CBD (Cannabidiol) and THC (Tetrahydrocannabinol) for pain control and inflammation in dogs. Currently in Phase 1B pharmacokinetic and safety clinical trials.
• CPAT-01C Extension of the CPAT-01 development program targeting pain control in cats. Preclinical and clinical research being conducted to GCP standards via Eurofins Animal Health.
• DermaCann Hemp-derived nutraceutical oral formulation being developed to promote optimal skin health in dogs. Contains Omega 3 and 6 fatty acids along with proprietary ingredients targeted towards treating allergic skin conditions.

Quantifiable outcome

• Phase 1A pharmacokinetic study completed with excellent safety profiles - no adverse events observed at target doses
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and supporting.

• University of MelbournecoreStrategic or Co-development Partner · 8 August 2018Memorandum of Understanding for veterinary research to conduct a pilot study determining efficacy of CBD treatment for epilepsy in dogs. Builds on CannPal's research pipeline including Phase 1B study for CPAT-01D and CPAT-01C for cats.
• Eurofins Animal HealthcoreStrategic or Co-development Partner · 8 July 2018Research services agreement for preclinical and clinical studies to GCP standards for CPAT-01C, the Company's cannabinoid-based pain treatment for cats. Eurofins is a world leader in food, environment, pharmaceutical testing and veterinary research services.
• Jaychem Industries LtdcoreOEM/ Whitelabel/ Licensing Partner · 29 May 2018Strategic manufacturing agreement with New Zealand-based GMP veterinary contract manufacturer for DermaCann, CannPal's lead nutraceutical product for canine skin health. Jaychem provides contract manufacturing services to GMP standards from their purpose-built facility operating since 1979.
• Seer PharmasupportingOthers · 1 May 2018Pharmaceutical quality assurance and GMP compliance consultants commissioned by CannPal to perform GMP Inspection of Jaychem Industries to relevant standards for Dermacann in target regions. Successfully completed audit finding Jaychem suitable for regulated nutraceutical manufacturing.
• CSIRO (Commonwealth Scientific and Industrial Research Organisation)coreStrategic or Co-development Partner · 1 April 2018Research agreement under CSIRO Kick-Start initiative providing dollar-matched funding (AUD$10,000-$50,000) for collaborative research into food production technologies to enhance delivery of CannPal's cannabis-derived therapeutic formulations. CSIRO is Australia's national science organization providing research expertise and facilities.
• Aphria Inc (TSE:APH)supportingTechnology or Integration · 27 March 2018Canadian licensed producer providing clinical trial material (medical cannabis oil formulations) for CPAT-01 studies. Aphria became the first Canadian licensed producer to receive cGMP accreditation from SGS to USFDA cGMP standards for pharmaceutical grade medicines.
• Dr. Jeffrey ShermansupportingOthers · 7 March 2018US-based board-certified animal health toxicology expert and consultant, former Elanco senior research scientist. Provides toxicological components for product dossiers and manages toxicological studies. Graduate of Ohio State University, diplomat of American Board of Toxicology.
• Klifovet AGsupportingStrategic or Co-development Partner · 1 January 2018One of Europe's largest veterinary research organisations and research partner. CannPal received Small and Medium-size Enterprise (SME) status with the European Medicines Agency (EMA) through collaboration with Klifovet.
• Invetus LimitedcoreStrategic or Co-development Partner · 1 January 2018Australasia's largest veterinary research organisation engaged to carry out initial phases of the clinical program for CPAT-01, the Company's lead drug candidate. Australasian partner for veterinary clinical research.
• Dr. Margaret CurtiscoreOthers · 1 November 2017Head of Clinical Development and R&D, former Elanco alumni with nearly two decades of experience. Held multiple director positions and gained approval for over 20 drugs in over 100 countries. Leads CannPal's research programs and regulatory strategies.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Canna-Pet: Developer of hemp-derived CBD products for companion animals. Directly comparable to CannPal as a cannabis/hemp-based pet therapeutics company, though Canna-Pet focuses on nutraceutical supplements rather than regulatory-approved pharmaceuticals.
• True Leaf Pet: Canadian company developing hemp-based functional treats and supplements for pets. Closely comparable to CannPal's DermaCann nutraceutical strategy and targets the same regulatory pathway for legal cannabis-derived pet products.
• Treatibles: CBD-based wellness products for pets including topicals and supplements. Comparable as a direct-to-pet-owner cannabis pet wellness brand, though operates in the unregulated/supplement space rather than prescription pharmaceuticals.

Broad incumbents

• Elanco Animal Health: Global animal health pharmaceutical leader and the former employer of CannPal's senior leadership. Represents the entrenched competitor CannPal aims to disrupt in the $1.4B+ canine pain/inflammation market with NSAIDs like Galliprant.
• Zoetis: World's largest animal health company with broad veterinary pharmaceutical portfolio including pain management (e.g., Rimadyl). Comparable as a major vet pharma competitor and potential commercialization partner.
• Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company focused on companion animal endocrinology, dermatology, and pain. Comparable for its specialty pharma positioning in dermatology and pain segments where CannPal's pipeline targets.
• Vetoquinol: Independent veterinary pharmaceutical company with strong dermatology and pain franchises. Comparable as a specialty vet pharma competitor, particularly relevant given CannPal's DermaCann dermatology focus.

Emerging players

• Phytecs: Cannabinoid therapeutics research company developing endocannabinoid system-targeted medicines. Comparable as an emerging player in cannabinoid-derived therapeutics with similar scientific approach.
• Indevia Pharmaceuticals: Emerging player in veterinary cannabinoid therapeutics. Comparable as a smaller competitor in the same niche targeting cannabinoid-based treatments for companion animals.

Regional players

• AusCann Group Holdings: CannPal's parent company (ASX:AC8) and Australian-listed cannabinoid pharmaceutical developer. Comparable as the corporate parent and as a fellow Australian-listed cannabinoid therapeutics developer, though focused on human medicines.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cannpal
• Xx.com/CannPalAT

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cannpal Animal Therapeutics